Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
NCT ID: NCT00688545
Last Updated: 2021-02-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
275 participants
OBSERVATIONAL
2009-04-30
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
NCT00652925
A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects
NCT01011959
CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry
NCT01402661
A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis
NCT00976599
A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis
NCT00134693
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Celecoxib
Patients treated with celecoxib as per treating physician's judgement
Celecoxib
Non-interventional: Treatment assignment as per treating physician's judgement
nsNSAIDs (nonselective nonsteroidal anti-inflammatory drugs)
Patients treated with nsNSAIDs as per treating physician's judgement
nsNSAIDs
Non-interventional: Treatment assignment as per treating physician's judgement
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Celecoxib
Non-interventional: Treatment assignment as per treating physician's judgement
nsNSAIDs
Non-interventional: Treatment assignment as per treating physician's judgement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* new treatment (started not more than 6 months prior) with one NSAID (celecoxib or nsNSAID).
Exclusion Criteria
* Patients with Reiter's syndrome; patients unlikely to complete 2 years of follow up;
* Patients who need to use multiple NSAIDs at the same time.
2 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Little Rock, Arkansas, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, United States
Pfizer Investigational Site
Arlington Heights, Illinois, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Glenview, Illinois, United States
Pfizer Investigational Site
New Lenox, Illinois, United States
Pfizer Investigational Site
Westchester, Illinois, United States
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Hackensack, New Jersey, United States
Pfizer Investigational Site
Livingston, New Jersey, United States
Pfizer Investigational Site
Brooklyn, New York, United States
Pfizer Investigational Site
Brooklyn, New York, United States
Pfizer Investigational Site
Commack, New York, United States
Pfizer Investigational Site
Great Neck, New York, United States
Pfizer Investigational Site
New Hyde Park, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Liberty Township, Ohio, United States
Pfizer Investigational Site
Mayfield Heights, Ohio, United States
Pfizer Investigational Site
Strongsville, Ohio, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sobel RE, Lovell DJ, Brunner HI, Weiss JE, Morris PW, Gottlieb BS, Chalom EC, Jung LK, Onel KB, Petiniot L, Goldsmith DP, Nanda K, Shishov M, Abramsky S, Young JP, Giannini EH; Pediatric Rheumatology Collaborative Study Group. Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry. Pediatr Rheumatol Online J. 2014 Jul 16;12:29. doi: 10.1186/1546-0096-12-29. eCollection 2014.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3191344
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.